Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic.
Features and Benefits
This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Psychiatry and clinical neurosciences, 66(2), 146-152 (2012-02-23)
Blonanserin is a second-generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti-5-HT(2A) activity/anti-D₂ activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. The subjects were 29 outpatients with schizophrenia. We assessed
Neuroleptic malignant syndrome induced by blonanserin.
Keiko Ohoyama et al.
The Journal of neuropsychiatry and clinical neurosciences, 23(1), E13-E13 (2011-02-10)
Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, 10(4), 198-200 (2010-12-17)
The aim of the present study was to determine the efficacy, side-effects and tolerability of blonanserin for treating refractory behavioural psychological symptoms of dementia (BPSD). The present study was a 12-week, prospective, structured clinical trial of blonanserin for the treatment
